MLH1 and Leigh syndrome: Their overall and progression-free survival are significantly worse than those of “suspected-LS” (cases with other MMR protein loss and MLH1/PMS2 loss without MLH1-silencing) [32,33]; in this way, “met-ECs” would be the main target for anti-PD-1 antibody treatment.